FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096869950> ?p ?o ?g. }

• W2096869950 endingPage "45" @default.
• W2096869950 startingPage "38" @default.
• W2096869950 abstract "Traumatic brain injury is a major cause of death and disability. We sought to assess the safety and efficacy of dexanabinol, a synthetic cannabinoid analogue devoid of psychotropic activity, in severe traumatic brain injury.861 patients with severe traumatic brain injury admitted to 86 specialist centres from 15 countries were included in a multi-centre, placebo-controlled, phase III trial. Patients were randomised to receive a single intravenous 150 mg dose of dexanabinol or placebo within 6 h of injury. The primary outcome was the extended Glasgow outcome scale assessed at 6 months, with the point of dichotomisation into unfavourable versus favourable outcome differentiated by baseline prognostic risk. Prespecified subgroup analyses were defined by injury severity, recruitment rate, and time to dosing. Secondary analysis included control of intracranial pressure and quality of life. Analysis were prespecified in the protocol and the statistical analysis plan. This study is registered with ClinicalTrials.gov, number NCT00129857.846 patients were included in the efficacy analysis. The extended Glasgow outcome scale at 6 months did not differ between groups; 215 (50%) patients in the dexanabinol group and 214 (51%) patients in the placebo group had an unfavourable outcome (odds ratio for a favourable response 1.04; 95% CI 0.79-1.36). Improvements in the control of intracranial pressure or quality of life were not recorded and subgroup analysis showed no indication of differential treatment effects. Dexanabinol was not associated with hepatic, renal, or cardiac toxic effects.Dexanabinol is safe, but is not efficacious in the treatment of traumatic brain injury." @default.
• W2096869950 created "2016-06-24" @default.
• W2096869950 creator A5012362990 @default.
• W2096869950 creator A5018371378 @default.
• W2096869950 creator A5046151553 @default.
• W2096869950 creator A5046564023 @default.
• W2096869950 creator A5057793733 @default.
• W2096869950 creator A5060137338 @default.
• W2096869950 creator A5066919763 @default.
• W2096869950 creator A5081079768 @default.
• W2096869950 creator A5084030156 @default.
• W2096869950 date "2006-01-01" @default.
• W2096869950 modified "2023-10-01" @default.
• W2096869950 title "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial" @default.
• W2096869950 cites W145468704 @default.
• W2096869950 cites W1572490995 @default.
• W2096869950 cites W1859440350 @default.
• W2096869950 cites W1948023428 @default.
• W2096869950 cites W1972491904 @default.
• W2096869950 cites W1979041225 @default.
• W2096869950 cites W1983808643 @default.
• W2096869950 cites W1987654866 @default.
• W2096869950 cites W1989883289 @default.
• W2096869950 cites W2009217495 @default.
• W2096869950 cites W2017132655 @default.
• W2096869950 cites W2024109107 @default.
• W2096869950 cites W2030403882 @default.
• W2096869950 cites W2045210813 @default.
• W2096869950 cites W2045663952 @default.
• W2096869950 cites W2068675481 @default.
• W2096869950 cites W2080282837 @default.
• W2096869950 cites W2082132862 @default.
• W2096869950 cites W2092258435 @default.
• W2096869950 cites W2118698655 @default.
• W2096869950 cites W2120398202 @default.
• W2096869950 cites W2135380777 @default.
• W2096869950 cites W2154634289 @default.
• W2096869950 cites W2333052542 @default.
• W2096869950 cites W4211164003 @default.
• W2096869950 doi "https://doi.org/10.1016/s1474-4422(05)70253-2" @default.
• W2096869950 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16361021" @default.
• W2096869950 hasPublicationYear "2006" @default.
• W2096869950 type Work @default.
• W2096869950 sameAs 2096869950 @default.
• W2096869950 citedByCount "241" @default.
• W2096869950 countsByYear W20968699502012 @default.
• W2096869950 countsByYear W20968699502013 @default.
• W2096869950 countsByYear W20968699502014 @default.
• W2096869950 countsByYear W20968699502015 @default.
• W2096869950 countsByYear W20968699502016 @default.
• W2096869950 countsByYear W20968699502017 @default.
• W2096869950 countsByYear W20968699502018 @default.
• W2096869950 countsByYear W20968699502019 @default.
• W2096869950 countsByYear W20968699502020 @default.
• W2096869950 countsByYear W20968699502021 @default.
• W2096869950 countsByYear W20968699502022 @default.
• W2096869950 countsByYear W20968699502023 @default.
• W2096869950 crossrefType "journal-article" @default.
• W2096869950 hasAuthorship W2096869950A5012362990 @default.
• W2096869950 hasAuthorship W2096869950A5018371378 @default.
• W2096869950 hasAuthorship W2096869950A5046151553 @default.
• W2096869950 hasAuthorship W2096869950A5046564023 @default.
• W2096869950 hasAuthorship W2096869950A5057793733 @default.
• W2096869950 hasAuthorship W2096869950A5060137338 @default.
• W2096869950 hasAuthorship W2096869950A5066919763 @default.
• W2096869950 hasAuthorship W2096869950A5081079768 @default.
• W2096869950 hasAuthorship W2096869950A5084030156 @default.
• W2096869950 hasConcept C118552586 @default.
• W2096869950 hasConcept C126322002 @default.
• W2096869950 hasConcept C142724271 @default.
• W2096869950 hasConcept C156957248 @default.
• W2096869950 hasConcept C168563851 @default.
• W2096869950 hasConcept C17624336 @default.
• W2096869950 hasConcept C187960798 @default.
• W2096869950 hasConcept C203092338 @default.
• W2096869950 hasConcept C204787440 @default.
• W2096869950 hasConcept C27081682 @default.
• W2096869950 hasConcept C2777796830 @default.
• W2096869950 hasConcept C2781017439 @default.
• W2096869950 hasConcept C42219234 @default.
• W2096869950 hasConcept C44249647 @default.
• W2096869950 hasConcept C535046627 @default.
• W2096869950 hasConcept C71924100 @default.
• W2096869950 hasConceptScore W2096869950C118552586 @default.
• W2096869950 hasConceptScore W2096869950C126322002 @default.
• W2096869950 hasConceptScore W2096869950C142724271 @default.
• W2096869950 hasConceptScore W2096869950C156957248 @default.
• W2096869950 hasConceptScore W2096869950C168563851 @default.
• W2096869950 hasConceptScore W2096869950C17624336 @default.
• W2096869950 hasConceptScore W2096869950C187960798 @default.
• W2096869950 hasConceptScore W2096869950C203092338 @default.
• W2096869950 hasConceptScore W2096869950C204787440 @default.
• W2096869950 hasConceptScore W2096869950C27081682 @default.
• W2096869950 hasConceptScore W2096869950C2777796830 @default.
• W2096869950 hasConceptScore W2096869950C2781017439 @default.
• W2096869950 hasConceptScore W2096869950C42219234 @default.
• W2096869950 hasConceptScore W2096869950C44249647 @default.
• W2096869950 hasConceptScore W2096869950C535046627 @default.

• next